Ninety One North America Inc. Sells 15,108 Shares of Johnson & Johnson $JNJ

Ninety One North America Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 270,748 shares of the company’s stock after selling 15,108 shares during the period. Johnson & Johnson comprises approximately 3.6% of Ninety One North America Inc.’s portfolio, making the stock its 5th largest position. Ninety One North America Inc.’s holdings in Johnson & Johnson were worth $71,678,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Trust Co. of Oklahoma raised its position in shares of Johnson & Johnson by 1.1% during the third quarter. Trust Co. of Oklahoma now owns 3,761 shares of the company’s stock worth $996,000 after acquiring an additional 41 shares during the last quarter. Purus Wealth Management LLC boosted its holdings in Johnson & Johnson by 3.9% in the third quarter. Purus Wealth Management LLC now owns 3,601 shares of the company’s stock valued at $953,000 after acquiring an additional 136 shares during the last quarter. Covenant Asset Management LLC boosted its holdings in Johnson & Johnson by 78.9% in the third quarter. Covenant Asset Management LLC now owns 22,724 shares of the company’s stock valued at $6,016,000 after acquiring an additional 10,024 shares during the last quarter. Kellett Wealth Advisors LLC increased its position in Johnson & Johnson by 2.3% during the 3rd quarter. Kellett Wealth Advisors LLC now owns 2,571 shares of the company’s stock valued at $681,000 after purchasing an additional 58 shares during the period. Finally, Colorado Capital Management Inc. increased its position in Johnson & Johnson by 2.5% during the 3rd quarter. Colorado Capital Management Inc. now owns 2,231 shares of the company’s stock valued at $591,000 after purchasing an additional 54 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.1%

Shares of NYSE:JNJ opened at $253.68 on Friday. The company has a market capitalization of $611.35 billion, a price-to-earnings ratio of 38.44, a P/E/G ratio of 2.59 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The business’s 50-day moving average is $265.73 and its 200-day moving average is $249.57. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the company earned $2.80 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts predict that Johnson & Johnson will post 11.10 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is 81.21%.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. HSBC raised their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Weiss Ratings raised shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $282.00 to $275.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Bank of America reissued a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $274.35.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share and revenue of $25.40 billion, exceeding consensus estimates. Revenue increased 5.9% year over year, led by 7.9% growth in Innovative Medicine. J&J Q3 2026 Earnings Call Transcript
• Positive Sentiment: Management raised its 2026 sales and earnings outlook, with guidance of approximately $11.05–$11.15 in adjusted EPS. Executives also highlighted pipeline products and MedTech innovation as potential sources of future growth. JNJ Q3 Earnings Call Highlights
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating, while RBC retained an “outperform” rating, indicating that analysts still see potential upside despite trimming their price targets. Technical analysts also identified support near $246. Morgan Stanley JNJ Price Target
• Neutral Sentiment: Johnson & Johnson plans an enterprise review on December 8 and is targeting a potential mid-2027 spinoff of its DePuy Synthes orthopedics business. These initiatives could clarify the company’s growth strategy but may also create execution and earnings-dilution concerns. J&J MedTech Orthopedics Spinoff
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness attributed partly to China pricing pressure and European budget cuts. Investors viewed the device business as a key reason the stock fell sharply following earnings. Johnson & Johnson Stock Falls as MedTech Misses
• Negative Sentiment: Analysts lowered several price targets after the results, citing mixed pharmaceutical trends, acquisition costs, talc-related charges and potential 2027 dilution. The concerns are more significant because JNJ trades at a premium earnings multiple versus the broader market. Analysts Cut JNJ Forecasts

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.